Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
CEL-SCI Corporation (NYSEMKT: CVM) shares jumped 12.50 percent to close at $1.26 a share Thursday. The stock traded between $1.13 and $1.30 on volume 3.82 million shares traded. The company announced that it has opened its first U.S. clinical site for its Phase III Head and Neck Cancer trial expansion. Shares of CEL-SCI are up approximately 110.0 percent year-to-date.
Get more information on CEL-SCI free access to the in-depth equity report at:
www.FiveStarEquities.com/CVM
Energy Recovery, Inc. (NASDAQ: ERII) shares soared 36.63 percent to close at $6.49 a share Thursday. The stock traded between $5.57 and $6.98 on volume of 7.63 million shares traded. The company reported net revenue was $23.2 million for the fourth quarter of 2013, an increase of 54.0 percent when compared to a year ago. Shares of Energy Recovery are up approximately 17.0 percent year-to-date.
Get more information on Energy Recovery and free access to the in-depth equity report at:
www.FiveStarEquities.com/ERII
La Jolla Pharmaceutical Company (NASDAQ: LJPC) shares spiked 12.67 percent to close at $8.89 a share Thursday. The stock traded between $8.42 and $9.75 on volume of 1.99 million shares traded. Chardan Capital Markets has recently initiated coverage on the company with a “buy” rating and a price target of $32.00. Shares of La Jolla Pharmaceutical are down approximately 1.5 percent year-to-date.
Get more information on La Jolla Pharmaceutical and free access to the in-depth equity report at:
www.FiveStarEquities.com/LJPC
Sangamo Biosciences, Inc. (NASDAQ: SGMO) shares surged 17.08 percent to close at $22.96 a share Thursday. The stock traded between $21.76 and $24.12 on volume 11.10 million shares traded. The company announced positive results from the first clinical study of its proprietary zinc finger nuclease (ZFN)-based genome editing technology in humans. Shares of Sangamo Biosciences are up approximately 65.0 percent year-to-date.
Get more information on Sangamo Biosciences and free access to the in-depth equity report at:
www.FiveStarEquities.com/SGMO
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
[email protected]